New 4Life Transfer Factor(R) Test Shows
73% Average Increase in Salivary IgA Production

4Life Research(TM) announced today the completion of a new preliminary scientific test showing the effect of 4Life Transfer Factor Tri-FactorŽ Formula on IgA antibody production. Participants took 4Life Transfer Factor Tri-Factor Formula for two weeks, followed by 4Life Transfer Factor RioVidaŽ Tri-Factor Formula for another two weeks. One hundred percent of participants saw an increase in the production rate of salivary secretory IgA when compared to a one-week baseline, with an average increase of 73%.

IgA antibodies, produced by plasma cells, are highly specific proteins used by the immune system to bind and neutralize foreign invaders. IgA bathes the surface of the mucous membranes. These y-shaped proteins bind to invaders, preventing them from attaching and passing through the mucous lining into the tissues and bloodstream of the body.

The test was conducted by 4Life Chief Executive Officer David Lisonbee; Chief Scientific Officer Calvin McCausland, Ph.D.; Health Sciences Advisory Board Member Richard Bennett, Ph.D.; Director of Health Information Services Brent Vaughan; and Research Scientist Shane Lefler.

"I'm proud to be associated with a company that values scientific research so highly," commented McCausland. "It's wonderful to provide effective immune system support products that are also backed up by sound scientific studies."

"I continue to be amazed at 4Life Transfer Factor's ability to boost and support the immune system," said Bennett. "This preliminary IgA test suggests another layer of vital immune system protection that 4Life Transfer Factor provides."

"4Life's Research and Development team has identified that 4Life Transfer Factor can support another vital component of a healthy immune system -- IgA antibodies -- once again proving our commitment to stay at the forefront of immune system science," remarked Lisonbee.

4Life, category creator of Transferceutical(TM) Science and world leader in the development, production, and distribution of Transfer Factor support products, continues to post growth in more than 50 countries around the world.